@article{8f0d2af6067043b5b734771f15482ad1,
title = "Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia",
abstract = "Three common missense variants of the Disrupted in Schizophrenia 1 (DISC1) gene, rs3738401 (Q264R), rs6675281 (L607F) and rs821616 (S704C), have been variably associated with the risk of schizophrenia. In a case-control study, we examine whether these gene variants are associated with schizophrenia and ultra-resistant schizophrenia (URS) in a population of French Caucasian patients. The URS phenotype is characterized according to stringent criteria as patients who experience no clinical, social and/or occupational remission in spite of treatment with clozapine and at least two periods of treatment with distinct conventional or atypical antipsychotic drugs. We find a significant association between DISC1 missense variants and URS. The association with rs3738401 remains significant after appropriate correction for multiple testing. These results suggest that the DISC1 rs3738401 missense variant is statistically linked with ultra-resistance to antipsychotic treatment.",
author = "F. Mouaffak and O. Kebir and M. Chayet and S. Tordjman and Vacheron, \{M. N.\} and B. Millet and N. Jaafari and A. Bellon and Oli{\'e}, \{J. P.\} and Krebs, \{M. O.\}",
note = "Funding Information: We thank all the patients and healthy volunteers involved in this study. The Psydev Team is also composed of Sophie Leroy, Katia Ossian, Narjes Bendjemaa, Franc¸oise Polides, Souhail Bannour and Marie-Jos{\'e}e Dos Santos. This work was supported by Institut National de la Sant{\'e} et de la Recherche M{\'e}dicale (Inserm), Centre Hospitalier Sainte Anne H{\^o}pital Sainte-Anne and by the Fondation Pierre Deniker. This study was supported by the Collaborative Network for Family Study in Psychiatry ({\textquoteleft}R{\'e}seau d{\textquoteright}{\'e}tude familiale en Psychiatry{\textquoteright}, REFAPSY), supported by the Fondation Pierre Deniker: H{\^o}pital Sainte-Anne, Paris SHU: MO Krebs; SM,13: Dr MN Vacheron, Dr A Viala; SM,17: Dr F Petitjean, Dr C Launay; SM,:18 Dr B Garnier, Dr B Dageyne; CMME, Paris: Pr J Guelfi, Dr C Even; Centre Hospitalier Sp{\'e}cialis{\'e} Les Mureaux : Dr G Naruse, Dr S Abbas, Dr A Anne, Dr T Loucif, Dr T Mouheb, Dr I Bardaune, Dr N Chellali-Gherab, Dr K Nissas, Dr P Cheminant; CH Guillaume R{\'e}gnier, Rennes: Pr S Tordjman, Pr B Millet, Dr D Levoyer, Dr S Gault; Etablissement Public de Sant{\'e} Erasme, Anthony: Dr JC Pascal, Dr M Shahidi; CHS Ville Evrard, Saint-Denis: Dr D Januel, Dr G Saba; Dr L Stamatiadis; CHU Strasbourg : Pr JM Danion, Dr A Baratta; H{\^o}pital Sud, Grenoble: Pr T Bougerol, Dr M Polosan; H{\^o}pital Laborit, Poitiers: Pr JL Senon, Dr N Jaafari, Dr S Rousse; CHU Bretonneau, Tours: Dr F Bonnet-Brilhault; Pr C Barth{\'e}l{\'e}my; Fondation Lenval, Nice: Pr F Askenazy, Y Seddiki. We also acknowledge Afsaneh Gray for the English editing of the paper.",
year = "2011",
month = aug,
doi = "10.1038/tpj.2010.40",
language = "English (US)",
volume = "11",
pages = "267--273",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Springer Nature",
number = "4",
}